Optimizing antibody–drug conjugates for cancer treatment

Greg Thurber (left) is an Associate Professor at the University of Michigan (MI, USA) based in the Chemical Engineering Department, Biomedical Engineering Department and the Rogel Cancer Center. He works with antibody–drug conjugates (ADCs), investigating their distribution within tumors to improve their therapeutic index. In this interview from this year’s meeting of the American Association for Cancer Research (5th-10th April; San Diego, CA, USA), we learn more about Thurber’s presentation and research on ADCs and the techniques he’s employing to enhance their therapeutic potential. What were three key messages from your presentation? The first was the importance of intra-tumoral ADC...